Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 800 Carcinoma, Non-Small-Cell Lung 755 Breast Neoplasms 726 Neoplasm Metastasis 336 Colorectal Neoplasms 336 Prostatic Neoplasms 320 Melanoma 303 Multiple Myeloma 302 Recurrence 236 Ovarian Neoplasms 233 Leukemia, Myeloid, Acute 232 Lymphoma, Non-Hodgkin 213 Lung Neoplasms 208 Carcinoma, Renal Cell 200 Lymphoma 187 Lymphoma, Follicular 163 Pancreatic Neoplasms 156 Leukemia, Lymphocytic, Chronic, B-Cell 149 Carcinoma, Hepatocellular 139 Stomach Neoplasms 135 Leukemia 130 Head and Neck Neoplasms 127 Lymphoma, Large B-Cell, Diffuse 125 Parkinson Disease 4, Autosomal Dominant Lewy Body 116 Squamous Cell Carcinoma of Head and Neck 109 Urinary Bladder Neoplasms 108 Carcinoma 101 Small Cell Lung Carcinoma 99 Triple Negative Breast Neoplasms 97 Glioblastoma 96

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡